Sodium-L-arginine succinate – a new vasodilating medicine for the treatment and prophylaxis of doxorubicin-induced cardiotoxicity

Abstract

The purpose: to ascertain possible cardioprotective effect of Sodium-L-arginine Succinate in case of myocardial lesions caused by Doxorubicin in rats. Methods. The effectiveness of the drug was assessed by morphometric and biochemical changes reflecting peroxidation intensity and structural and functional changes in myocardium. Results. Sodium-L-arginine Succinate used for the treatment and prophylaxis of antracyclic cardiomyopathy was demonstrated to decrease Doxorubicin effects lessening cardiomyocytal destruction and the left ventricular dysfunction with myocardial hypertrophy.